Clinical trialNCT06504381RecruitingPhase 1/PHASE2Interventional

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

SponsorUniversity of California, San FranciscoEnrollment70High Grade GliomaMGMT-Methylated GlioblastomaMGMT-Unmethylated Glioblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC when added to standard of care provides clinical benefit to newly diagnosed HGG when compared to historical performance previously determined in well controlled clinical trials published in the peer reviewed literature. This study is going to be conducted in newly diagnosed HGG patients receiving with maximum surgical resection treatment followed by radiation and temozolomide treatment using the established Stupp Protocol for O6-methylguanine-DNA methyl-transferase (MGMT) methylated patients or radiation therapy for MGMT unmethylated patients.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Nicholas Butowski, MD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗
Noriyuki Kasahara, MD, PhD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Southern California
Los Angeles, California, United States
Thomas Chen, MD
Recruiting
University of California, San Diego
San Diego, California, United States
David Piccioni, MD, PhD
Recruiting
University of California
San Francisco, California, United States
Nicholas Butowski, MDNoriyuki Kasahara, MD, PhD
Recruiting
University of Miami
Miami, Florida, United States
Ashish Shah, MD
Recruiting
Northwell Health
Lake Success, New York, United States
Samuel Singer, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DB107-FCTemozolomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Jan 2025
Primary completion: 31 Jan 2028
Completion: 31 Jan 2042
Last update posted: 11 Mar 2026
Registered enrollment: 70
Registry id: NCT06504381

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.